For the quarter ending 2025-09-30, GYRE had $3,911K increase in cash & cash equivalents over the period. $4,008K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income | 5,936 | 5,310 |
| Accounts and note receivables | - | 4,966 |
| Stock-based compensation | 1,147 | 1,413 |
| Equity in loss of unconsolidated affiliate | -19 | -38 |
| Depreciation and amortization | 649 | 1,176 |
| Noncash lease expense | 206 | 400 |
| Deferred income taxes | -531 | -491 |
| Bad debt expense and other non-cash items | -54 | 25 |
| Accrued interest on certificates of deposit | 267 | -189 |
| Change in fair value of long-term receivable | 0 | 39 |
| Change in fair value of derivative liabilities | 0 | 39 |
| Change in fair value of warrant liability | 23 | -2,467 |
| Loss on disposal of property and equipment | -1 | -1 |
| Notes receivable | 178 | -3,879 |
| Accounts receivable | 5,981 | - |
| Inventories | -72 | 2,495 |
| Prepaid and other assets | -398 | 95 |
| Income tax payable | 1,536 | -1,753 |
| Accounts payable | 483 | -37 |
| Accrued expenses and other liabilities | -3,513 | 2,079 |
| Operating lease liabilities | -236 | -272 |
| Net proceeds from cvr liability settlement | 0 | 25 |
| Net cash provided by (used in) operating activities | 4,676 | 1,959 |
| Purchase of short-term investments | 564 | - |
| Acquisition of intangible assets | 15 | 722 |
| Purchase of certificates of deposit | 0 | 11,184 |
| Purchase of property and equipment | 668 | 378 |
| Proceeds from the sale of equipment | 0 | 19 |
| Maturity of certificates of deposit | 0 | 11,190 |
| Net cash used in investing activities | -1,247 | -1,075 |
| Offering costs paid | -315 | 1,802 |
| Proceeds from the exercise of stock options | 50 | 1,988 |
| Proceeds from the issuance of common stock-May Two Thousand Twenty Five Underwritten Public Offering | 0 | 23,000 |
| Proceeds from the issuance of common stock-Two Thousand Twenty Four ATMProgram | 0 | 509 |
| Net cash provided by financing activities | 365 | 23,695 |
| Effect of exchange rate changes on cash and cash equivalents | 117 | 99 |
| Net increase (decrease) in cash and cash equivalents | 3,911 | 24,678 |
| Cash and cash equivalents at beginning of period | 11,813 | - |
| Cash and cash equivalents at end of period | 40,402 | - |
GYRE THERAPEUTICS, INC. (GYRE)
GYRE THERAPEUTICS, INC. (GYRE)